What Are the Stages of Neuropathy Progression?

Neuropathy generally progresses through a recognizable sequence, starting with damage to the smallest, most vulnerable nerve fibers and advancing toward larger fibers that control strength and coordination. The widely used clinical staging system developed by neurologist P.J. Dyck describes this trajectory in graded steps, from subclinical nerve changes detectable only on testing, through symptomatic sensory loss, to disabling weakness and autonomic dysfunction.¹ But the pace and pattern vary enormously depending on the cause, and not everyone moves through every stage.

The Earliest Changes You Cannot Feel

Before you notice anything wrong, nerve damage has usually been underway for a while. The first fibers to deteriorate are the smallest unmyelinated and thinly myelinated ones, called small fibers, which carry pain, temperature, and some autonomic signals. These fibers extend to the surface of your skin, and their density can be measured with a tiny skin punch biopsy. In one prospective study of people with diabetes who had no neuropathy symptoms, about a third already showed reduced nerve fiber density in the skin at baseline, and a similar proportion had abnormal findings on corneal confocal microscopy, a non-invasive way to image small nerves in the eye.² That means damage can be measurable long before the classic tingling and burning show up.

When symptoms do appear, they usually start in the toes and feet. The pattern is called “stocking-glove” because it follows the length of the nerves: the longest fibers, running from the spinal cord all the way to the toes, are the most metabolically vulnerable and tend to fail first. Early complaints are typically intermittent burning, prickling, or an exaggerated sensitivity to touch. Some people describe a feeling like walking on sand or pebbles. At this stage, a standard nerve conduction study may still come back normal, because those tests primarily measure the larger, faster-conducting fibers that have not yet been affected.

How Sensory Loss Deepens

As damage extends to the larger myelinated sensory fibers, the character of the problem shifts. Instead of too much sensation (burning, tingling), you start losing sensation altogether. Vibration sense in the toes fades. The ability to tell where your feet are in space, called proprioception, diminishes. This is the stage where balance gets noticeably worse, especially in the dark or on uneven ground, because your brain is no longer getting reliable position data from the feet. Research in animal models has shown that even partial loss of large sensory fibers disrupts the organized muscle activation patterns the body uses to recover balance after a stumble.³

Nerve conduction studies become clearly abnormal at this point. A useful clinical distinction emerges here between two broad patterns of damage. In axonal neuropathies, where the nerve fiber itself is degenerating, conduction speeds tend to slow more when measured from distant muscles in the feet while staying relatively normal closer to the spine. In demyelinating neuropathies, where the insulating sheath around the nerve is the primary target, conduction slows uniformly throughout the nerve’s length.⁴ This distinction matters because it points toward different causes and different treatment options.

The stocking-glove pattern continues to creep upward during this phase. Numbness that started in the toes reaches the ankles, then the mid-calf. Once it passes the knees, the fingertips often begin losing sensation too, because the nerves reaching the hands are now the same length as the already-damaged leg nerves. A systematic review found that worsening peripheral nerve function at various levels of severity was consistently associated with poor mobility in older adults, independent of whether they had diabetes.⁵

When Motor Nerves Get Involved

In many forms of neuropathy, motor fibers are affected later than sensory ones, though the timing depends heavily on the underlying cause. When motor nerves do deteriorate, the muscles they supply begin to weaken and eventually waste. The intrinsic muscles of the feet, which help maintain the arch and keep the toes straight, are among the first to go. That leads to visible foot deformities: claw toes, a high arch, and prominent metatarsal heads on the sole. These bony changes redistribute pressure during walking in ways that set the stage for skin breakdown and ulcers.

In some neuropathies, motor involvement can be the dominant feature rather than an afterthought. One reported case of anti-MAG neuropathy, an immune-mediated condition, presented with severe muscle weakness and extensive muscle wasting that mimicked a hereditary nerve disorder, even though nerve conduction studies showed the characteristic pattern of that particular antibody.⁶ The point is that the textbook order of sensory-then-motor does not hold for every patient or every cause.

Functionally, the motor stage is when daily life becomes notably harder. A study of people receiving paclitaxel chemotherapy found that by week five, more than half reported difficulty buttoning clothes, nearly half had trouble with writing, and about the same proportion struggled with walking and climbing stairs.⁷ These are not abstract clinical measures but the everyday tasks that define independence.

The Autonomic Dimension

Peripheral nerves do not just carry sensation and muscle commands. They also run the involuntary systems that control heart rate, blood pressure regulation, sweating, digestion, and bladder function. Autonomic neuropathy often develops in parallel with the sensory and motor stages, but it tends to be recognized later because its symptoms are vague and easy to attribute to other causes: lightheadedness on standing, unpredictable bowel habits, difficulty with sexual function.

In diabetic autonomic neuropathy affecting the heart, preclinical imaging research has revealed a specific order to the damage. Parasympathetic nerve fibers (the “rest and digest” system) deteriorate first, followed by sympathetic fibers (the “fight or flight” system) weeks later.⁸ This sequence matters clinically because it explains why an early sign of cardiac autonomic neuropathy is a resting heart rate that stays inappropriately fast: the parasympathetic brake is gone, but the sympathetic accelerator is still working.

Sweat gland function turns out to be a useful window into autonomic nerve health. In a study of people diagnosed with cardiac autonomic neuropathy, those with the condition showed measurably lower sweat gland activity in their hands and especially their feet compared to those without it. Among people who had cardiac autonomic neuropathy, roughly 41% were classified as mild, 47% as moderate, and about 12% as severe.⁹ That distribution suggests most people are caught before the worst stage, but it also reflects the difficulty of diagnosing the condition early.

Loss of Protective Sensation and Its Consequences

One of the most clinically important thresholds in neuropathy progression is the loss of protective sensation, the point at which your feet can no longer detect forces strong enough to cause tissue damage. This is not an abstract concept. A study of leprosy patients in rural India found that people who could detect a 10-gram monofilament pressed against the sole of the foot were protected from developing ulcers, while those who could only feel a 30-gram filament were not.¹⁰ The protective threshold lies somewhere between those two pressures.

Once that threshold is crossed, the risk of foot ulcers climbs steeply. In a prospective study of people with diabetes, those who had lost protective pain sensation were about three times more likely to develop a first foot ulcer, and the time to developing that ulcer was roughly half compared to those who retained sensation.¹¹ Foot ulcers are the leading cause of non-traumatic lower-limb amputations, so this stage of neuropathy carries consequences far beyond discomfort. This is also why routine foot exams with monofilament testing are a cornerstone of diabetes care: catching loss of protective sensation early lets clinicians and patients intervene with footwear modifications, regular skin checks, and podiatric care before an ulcer forms.

What Is Actually Happening Inside the Nerve

The characteristic pattern of most peripheral neuropathies is called “dying-back” degeneration. The nerve fiber does not collapse all at once; instead, its farthest tip starts to wither and the damage works its way back toward the cell body in the spinal cord or dorsal root ganglion. This explains the stocking-glove pattern: the longest fibers are the first to show visible damage because they have the most distant tips.

Recent research has identified a key molecular player in this process: a protein called SARM1. When nerves are stressed by metabolic damage, toxins, or other insults, SARM1 acts as an executioner, triggering a self-destruction program in the axon. This is not just a feature of traumatic nerve injury. Studies have shown that SARM1 drives the gradual, chronic axon loss that defines peripheral neuropathy and other neurodegenerative conditions.¹² Upstream of SARM1 activation, mitochondrial dysfunction appears to be a common trigger. In models of toxic neuropathy, damage to mitochondria within the nerve fiber activates the SARM1 destruction pathway, and genetically deleting SARM1 rescues neurons from dying.¹³ This has made SARM1 a promising drug target, with several pharmaceutical programs exploring SARM1 inhibitors for neuropathy.

Research has also clarified that the cell death mechanisms involved are not always the orderly programmed death (apoptosis) that textbooks describe. In at least some forms of toxic neuropathy, motor neurons undergo a more inflammatory form of cell death called necroptosis, which involves damage to mitochondria and the activation of specific destructive proteins that converge on the SARM1 pathway.¹⁴ Understanding these details is not just academic; it is shaping the next generation of treatments.

How the Cause Changes the Timeline

The stages described above represent the general pattern, but the pace and emphasis change dramatically depending on what is causing the neuropathy.

In diabetic neuropathy, the most common cause, progression tends to be slow and steady over years. Prolonged high blood sugar leads to cumulative nerve damage, and elevated HbA1c levels track with increasing neuropathy risk.¹⁵ Intensive blood sugar control can slow the arrival of new neuropathy. In a large trial of people with type 2 diabetes, an insulin-sensitizing strategy was associated with a lower four-year incidence of new neuropathy compared to an insulin-providing strategy. However, among those who already had neuropathy at the start, neither approach improved the remission rate.¹⁶ That asymmetry is critical: preventing progression is much more achievable than reversing it.

Chemotherapy-induced neuropathy follows a different pattern. It typically begins during treatment and can worsen for weeks to months after the last dose, a phenomenon called “coasting.” A systematic review of taxane-induced neuropathy in breast cancer patients found that coasting was clearly documented in one study, where about 14% of patients saw their neuropathy worsen from mild to severe after treatment ended. Eight studies found no coasting or reported that symptoms resolved after treatment; the rest were unclear.¹⁷ The unpredictability of coasting makes it harder for oncologists and patients to plan.

Hereditary neuropathies like Charcot-Marie-Tooth disease (CMT) typically progress very slowly over decades. In children, CMT is the most common hereditary peripheral neuropathy, presenting with delayed motor milestones, weakness, and foot deformities.¹⁸ A longitudinal study of Brazilian children with CMT found that disease scores worsened by about 4.5 points over two years, with measurable decline within just one year, particularly in hand dexterity, sensation, and walking ability.¹⁹ Even though the total disability accumulates slowly, the year-over-year changes are real and worth tracking.

Inflammatory neuropathies like chronic inflammatory demyelinating polyneuropathy (CIDP) break the mold entirely. Rather than a steady downhill slope, CIDP can follow a relapsing-remitting course with acute flares of weakness and sensory loss separated by periods of partial recovery. About 5% of patients initially diagnosed with Guillain-Barré syndrome actually turn out to have an acute-onset form of CIDP, highlighting how easily the two can be confused early on.²⁰ The key difference is that CIDP is treatable with immunotherapy, making accurate diagnosis especially high-stakes.

Tracking Progression With Biomarkers and Nerve Studies

Traditionally, neuropathy staging has relied on clinical scoring systems and nerve conduction studies. These remain the backbone of evaluation, but newer tools are adding resolution, especially at the early and monitoring stages.

Medial plantar nerve conduction studies can pick up diabetic neuropathy earlier than standard sural nerve testing, because the medial plantar nerve runs through the foot and is among the first to show measurable changes.²¹ For chemotherapy-induced neuropathy, monitoring the sural nerve response during treatment has shown promise for predicting who will develop clinically significant neuropathy. A decline of 35% or more in the sural nerve response from baseline to mid-treatment was strongly associated with needing a dose reduction for neurotoxicity.²²

Blood biomarkers are gaining traction as well. A meta-analysis found that people with peripheral neuropathy have significantly elevated blood levels of neurofilament light chain (NfL), a protein released when nerve fibers are damaged.²³ Higher NfL levels correlate with greater disease severity across several types of neuropathy, including Charcot-Marie-Tooth disease, chemotherapy-induced neuropathy, and inflammatory neuropathies.²⁴ NfL is not specific to neuropathy (it rises in many neurological conditions), but it is useful for monitoring treatment response. Routine NfL testing is considered especially valuable in situations like treatment-resistant inflammatory neuropathy or hereditary amyloid neuropathy, where knowing whether active nerve damage is ongoing directly influences therapeutic decisions.²⁵

When the Brain Starts to Change Too

Neuropathy is a disease of the peripheral nerves, but sustained peripheral nerve damage eventually rewires parts of the central nervous system. This process, known as central sensitization, helps explain why some people with neuropathy develop pain that seems disproportionate to the degree of nerve damage visible on testing, and why the pain can persist even after the original peripheral trigger stabilizes.

What happens is that the spinal cord neurons receiving signals from damaged peripheral nerves become hyperexcitable. They start amplifying incoming signals, so that a light touch is processed as painful and low-grade nerve firing is experienced as burning or aching. Reviews of painful diabetic neuropathy have concluded that these central nervous system changes are a prominent feature of the condition, not a rare exception.²⁶

The spinal cord does not act alone. Once hyperexcitable spinal neurons relay their exaggerated signals upward, brainstem areas involved in emotional and autonomic responses to pain get activated. Those brainstem areas then send signals back down to the spinal cord, establishing a feedback loop that sustains and sometimes worsens the pain state.²⁷ This loop is one reason neuropathic pain can be so stubborn to treat with medications that target only the peripheral nerves. Drugs that work on the central nervous system, like certain antidepressants and anticonvulsants used for neuropathic pain, are partly targeting this amplification circuit. Recognizing central sensitization as a stage in neuropathy progression, rather than a separate problem, is reshaping how clinicians think about pain management in people whose peripheral nerve damage has reached moderate or advanced stages.